INTRANASAL LHRH AGONIST TREATMENT FOR INHIBITION OF OVULATION IN WOMEN: CLINICAL ASPECTS

Authors:
  • CBChrister Bergquist
    Christer Bergquist
  • SNSven Johan Nillius
    Sven Johan Nillius
  • LWLeif Wide
    Leif Wide

Abstract
Daily intranasal administration of the potent stimulatory LHRH analog D-Ser(TBU)6-EA10-LHRH was given to 50 healthy women for 3 mo. Twenty-six women received 400 .mu.g LHRH agonist/day and 24 women received 600 .mu.g/day. Inhibition of ovulation occurred during 147 of the 150 treatment months. The 3 presumptively ovulatory cycles were probably the result of initial technical problems with the nasal spray. No pregnancies occurred. Reactivation of corpus luteum with slightly raised progesterone levels in serum at initiation of treatment was observed in 6 women. During 20 mo. of treatment the serum progesterone levels were slightly raised, indicating luteinization of follicles or defect luteal phases. Most of the women had menstrual-like bleeding during treatment. Seventeen volunteers had regular bleeding and 23 women had oligomenorrhea. No dysfunctional uterine bleeding occurred, but 3 women reported spotting. The remaining 10 women had amenorrhea during treatment without any symptoms of estrogen deficiency. After discontinuation of treatment the women regained ovulatory menstrual cycles after 31 days on average. The treatment was very well accepted by all the women.

This publication has 16 references indexed in Scilit: